Please try another search
Nuevolution AB (publ), a biopharmaceutical company, focuses on developing drug treatments for oncology and chronic inflammatory diseases. The company offers Chemetics, a drug discovery platform, which enables the discovery of small molecule drug candidates. It develops ROR?t Inhibitor for the treatment of chronic inflammatory diseases; Bromodomain BET BD1 selective inhibitor to treat chronic inflammatory diseases and cancer; and IL-17A inhibitor program for chronic inflammatory diseases. The company also develops ROR?t Agonist to treat immuno-oncology; and GRP78 for the treatment of oncology. It has license and collaboration agreements with Amgen; Almirall; and Janssen Biotech, Inc. Nuevolution AB (publ) was founded in 2001 and is headquartered in Copenhagen, Denmark. Nuevolution AB (publ) operates as a subsidiary of Amgen Inc.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review